Related Experiment Video
Updated: Oct 12, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Targeting of the FOXM1 Oncoprotein by E3 Ligase-Assisted Degradation
Guoshun Luo1, Xin Lin1, Antonio Vega-Medina2
1State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 211198, P. R. China.
Abstract:
The transcription factor FOXM1 that regulates multiple proliferation-related genes through selective protein-DNA and protein-protein interactions is now considered an attractive oncotarget. There are several small-molecule inhibitors that indirectly suppress the expression of FOXM1 or block its DNA binding domain (FOXM1-DBD). However, insufficient specificity or/and efficacy are two potential drawbacks. Here, we employed in silico modeling of FOXM1-DBD with inhibitors to enable the design of an effective CRBN-recruiting molecule that induced significant FOXM1 protein degradation and exerted promising in vivo antitumor activity against TNBC xenograft models. This study is the first of its kind showcasing the use of an approach described in the literature as protein-targeting chimeras to degrade the elusive FOXM1, providing an alternative strategy to counter the pathological effects resulting from the increased transcriptional activity of FOXM1 observed in cancer cells.
Insights
Researchers designed a novel molecule to degrade the FOXM1 oncoprotein, a key target in cancer. This protein-targeting chimera approach shows promise for treating triple-negative breast cancer (TNBC).
Area of Science:
- Molecular Oncology
- Drug Discovery
Background:
- The transcription factor FOXM1 is a crucial regulator of proliferation-related genes and an attractive target in oncology.
- Current small-molecule inhibitors targeting FOXM1 often suffer from insufficient specificity and efficacy.
Purpose of the Study:
- To design an effective CRBN-recruiting molecule for targeted FOXM1 protein degradation.
- To evaluate the in vivo antitumor activity of the designed molecule against triple-negative breast cancer (TNBC) xenografts.
Main Methods:
- Utilized in silico modeling of the FOXM1 DNA-binding domain (FOXM1-DBD) with inhibitors.
- Developed a novel protein-targeting chimera strategy to induce FOXM1 protein degradation.
Main Results:
- Successfully designed a CRBN-recruiting molecule that effectively degrades FOXM1 protein.
- Demonstrated promising in vivo antitumor activity in TNBC xenograft models.
Conclusions:
- This study pioneers the use of protein-targeting chimeras to degrade the challenging FOXM1 oncoprotein.
- Presents a novel therapeutic strategy to counteract the oncogenic role of FOXM1 in cancer.
Related Concept Videos
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
PI3K/mTOR/AKT Signaling Pathway
Abnormal Proliferation
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
mRNA Stability and Gene Expression
Cis-acting Elements involved in mRNA stability

